Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Down 36.9% in March

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 1,250,000 shares, a decrease of 36.9% from the February 28th total of 1,980,000 shares. Approximately 2.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,640,000 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Trading of Cardio Diagnostics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Securities LLC purchased a new position in Cardio Diagnostics in the 4th quarter valued at about $48,000. Jane Street Group LLC acquired a new position in shares of Cardio Diagnostics in the fourth quarter valued at approximately $103,000. Millennium Management LLC purchased a new position in shares of Cardio Diagnostics during the fourth quarter valued at approximately $236,000. Finally, Geode Capital Management LLC boosted its position in Cardio Diagnostics by 97.6% during the fourth quarter. Geode Capital Management LLC now owns 364,387 shares of the company’s stock worth $334,000 after acquiring an additional 179,978 shares during the last quarter. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Cardio Diagnostics Price Performance

Cardio Diagnostics stock opened at $0.38 on Friday. Cardio Diagnostics has a fifty-two week low of $0.19 and a fifty-two week high of $1.77. The stock has a fifty day moving average of $0.48 and a two-hundred day moving average of $0.48.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.